Live Breaking News & Updates on Cevec Capr Technology
Stay updated with breaking news from Cevec capr technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CEVEC Pharmaceuticals GmbH: CEVEC and UCB Sign Agreement for the use of CEVEC's ELEVECTA AAV Manufacturing Technology in Gene Therapy finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
DGAP-News: CEVEC and UCB sign agreement for the use of CEVEC's ELEVECTA(R) AAV manufacturing technology in Gene Therapy boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.
CEVEC Pharmaceuticals GmbH: CEVEC Closes Growth Financing Round to Serve Strong Demand in Viral Vector Technologies for Cell and Gene Therapies finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Press release content from Accesswire. The AP news staff was not involved in its creation. CEVEC and CARISMA Therapeutics Sign License Agreement for the Use of CAP(R) Technology in Anti-Tumor Cell Therapies February 2, 2021 GMT CARISMA receives full rights to use the CAP(R) Technology for the production of adenoviral vectors across their whole portfolio of cell therapies for oncology applications CEVEC’s unique CAP(R) cells are specifically designed for highly scalable, RCA-free adenoviral vector manufacturing in suspension bioreactors The agreement supports CARISMA’s development of novel CAR-macrophage immunotherapies, a first-of-its-kind approach to the treatment of solid tumors COLOGNE, GERMANY and PHILADELPHIA, PA / ACCESSWIRE / February 2, 2021 / CEVEC Pharmaceuticals GmbH (CEVEC) and CARISMA Therapeutics Inc. (CARISMA) today announced the signing of an agreement which grants CARISMA a clinical and commercial license for CEVEC’s proprietary CAP(R ....
(0) DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s): Alliance CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP(R) Technology in anti-tumor cell therapies 02.02.2021 / 14:00 The issuer is solely responsible for the content of this announcement. CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP(R) Technology in anti-tumor cell therapies CARISMA receives full rights to use the CAP(R) Technology for the production of adenoviral vectors across their whole portfolio of cell therapies for oncology applications CEVEC s unique CAP(R) cells are specifically designed for highly scalable, RCA-free adenoviral vector manufacturing in suspension bioreactors The agreement supports CARISMA s development of novel CAR-macrophage immunotherapies, a first-of-its-kind approach to the treatment of solid tumors ....